Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Vivos Inc.

Market Cap 30.14M 26.15M 24.11M 22.59M 42.2M 2.89B 43.08M 288M 111M 1.39B 113M 111M 4.84B P/E Ratio 2024
-16.2x
P/E Ratio 2025 -10.2x
Enterprise Value 28.69M 24.9M 22.95M 21.51M 40.18M 2.75B 41.02M 274M 106M 1.32B 108M 105M 4.6B EV / Sales 2024
1,724x
EV / Sales 2025 438x
Free-Float
95.83%
Yield 2024 *
-
Yield 2025 -
1 day+0.74%
1 week+1.32%
Current month-10.74%
1 month-2.84%
3 months-26.79%
6 months-5.38%
Current year-10.74%
1 week 0.06
Extreme 0.0561
0.07
1 month 0.06
Extreme 0.0561
0.07
Current year 0.06
Extreme 0.0561
0.09
1 year 0.04
Extreme 0.0425
0.15
3 years 0.04
Extreme 0.0412
0.26
5 years 0.04
Extreme 0.04
0.26
10 years 0.01
Extreme 0.0065
8
Manager TitleAgeSince
Chief Executive Officer 79 13/12/2016
President 44 14/09/2025
Director of Finance/CFO 59 30/11/2018
Director TitleAgeSince
Chairman 81 13/12/2016
Director/Board Member 79 01/08/2017
Date Insider Type Main position Quantity % Market Cap.
05-10Buy

Chief Executive Officer

150,000 0.0311%
12-30Buy

Chief Executive Officer

200,000 0.0440%
12-01Buy

Chief Executive Officer

100,000 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%+1.32%-50.00%+14.31% 30.14M
+1.46%-1.84%-14.84%-17.97% 13.39B
+1.59%-8.19%+84.54%+12.63% 5.1B
-1.55%-4.42%-44.00%-68.58% 1.23B
+0.36%+1.42%+58.14%+99.66% 1.23B
-2.57%-10.27%-37.31%-43.79% 1.21B
-1.41%-7.09%-43.08% - 941M
+0.86%-4.48%+188.95%+181.29% 706M
-3.73%-7.43% - - 362M
+9.46%+5.40%-59.44%+189.33% 216M
Average +0.52%-2.28%+9.22%+45.86% 2.44B
Weighted average by Cap. +0.95%-1.96%+11.78%-0.94%

Financials

2024 2025
Net sales 28K 24.29K 22.39K 20.98K 39.21K 2.68M 40.02K 267K 103K 1.29M 105K 103K 4.49M 68.38K 59.34K 54.7K 51.25K 95.76K 6.55M 97.75K 652K 253K 3.16M 257K 251K 10.97M
Net income -2.91M -2.53M -2.33M -2.18M -4.08M -279M -4.16M -27.77M -10.75M -134M -10.93M -10.69M -467M -3.07M -2.66M -2.45M -2.3M -4.29M -294M -4.38M -29.26M -11.33M -142M -11.51M -11.26M -492M
Net Debt -2.21M -1.92M -1.77M -1.66M -3.1M -212M -3.16M -21.11M -8.17M -102M -8.31M -8.13M -355M -1.44M -1.25M -1.16M -1.08M -2.02M -138M -2.06M -13.78M -5.34M -66.66M -5.42M -5.3M -232M
Logo Vivos Inc.
Vivos Inc. is a radiation oncology medical device company. The Company has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Employees
1
Date Price Change Volume
11/06/26 0.0615 $ +0.74% 201,018
10/06/26 0.0610 $ +0.58% 387,576
09/06/26 0.0607 $ -2.10% 738,974
08/06/26 0.0620 $ +1.97% 548,250
05/06/26 0.0608 $ +0.16% 1,388,243
  1. Stock Market
  2. Stocks
  3. RDGL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!